Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001699737-26-000007·Kalaris Therapeutics, Inc.
Schedule 13D ownership disclosure
KALARIS THERAPEUTICS INC
Common Stock, $0.0001 par value per share · CUSIP: 482929106
Event date: 2025-12-18
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Samsara BioCapital, L.P.Reported CIK 0001699737
Shares: 10,968,234.00 · Class: 47.9%
- Samsara BioCapital GP, LLCReported CIK 0001888829
Shares: 10,968,234.00 · Class: 47.9%
- Samsara Opportunity Fund, L.P.Reported CIK 0002086193
Shares: 1,979,847.00 · Class: 8.6%
- Samsara Opportunity Fund GP, LLCReported CIK 0002086456
Shares: 1,979,847.00 · Class: 8.6%
- Srinivas AkkarajuReported CIK 0001253170
Shares: 12,954,081.00 · Class: 56.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001699737-26-000007
- Form type
- SCHEDULE 13D/A
- Filer
- Kalaris Therapeutics, Inc.
- CIK
- CIK 1754068
- Filed
- Feb 17, 2026
- Reporting period
- Dec 18, 2025
- Description
- Schedule 13D beneficial ownership